Abstract: Novel sulphones of Formula I are disclosed: wherein A completes a 4-7 membered ring optionally comprising up to two heteroatoms. The compounds modulate the action of ?-secretase and are therefore useful in the treatment or prevention of Alzheimer's disease.

Abstract: A process for preparing organic compounds of the general formula (I) R—R???(I), where R is a substituted or unsubstituted aromatic, heteroaromatic, cycloalkenylic or alkenylic radical and R? is a substituted or unsubstituted alkylic, alkenylic, cycloalkylic or cycloalkenylic radical, by reacting a corresponding compound of the general formula (II) R—X??(II), where X is chlorine, bromine, iodine, diazonium, mesylate (methanesulphonate), tosylate (p-toluenesulphonate) or triflate (trifluorosutphonate) and R is as defined for formula (I), with a corresponding compound of the general formula (III) R?—Y??(III), where Y is chlorine, bromine or iodine and R? is as defined for formula (I), wherein the reaction is carried out in the presence of a) stoichiometric amounts of elemental magnesium, based on the compound of the general formula (II), and b) catalytic amounts of a transition metal compound, based on the compound of the general formula (II), and, if appropriate, c) in the presence of a

Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

Abstract: Compounds of formula (Ia): where x, y, G, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, are disclosed, as well as pharmaceutical compositions comprising the compounds. These compounds and pharmaceutical compositions are useful in treating SCD-mediated diseases or conditions.

Abstract: The present invention relates to a compound of formula I wherein R1, R2, R3, R4, R9, R10, m and n are as defined herein, or to a pharmaceutically acceptable acid addition salt thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, bipolar disorders, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Abstract: Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract: The object is to provide a light-emitting transistor material which is high in both luminescent property and mobility when used as a light-emitting transistor device. A light-emitting transistor device is provided in which light emission of a specific pyrene-based organic compound is used for a light-emitting layer of a transistor device.

Abstract: Provided is a new organic-acid-based catalyst enabling production of a polyhydroxycarboxylic acid by direct dehydration polycondensation of a hydroxycarboxylic acid such as L-lactic acid, specifically, an organic-acid-based catalyst comprising an amine salt of a sulfonic acid or a phosphine salt of a sulfonic acid for production of polyhydroxycarboxylic acids such as poly-L-lactic acid.

Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Abstract: The present invention discloses compounds of Formula I wherein V, W, Y, Z, R1, R2, R3, R4, d, m, n, p and r are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

Abstract: Monocyclopentadienyl complexes in which the cyclopentadienyl system bears at least one unsubstituted, substituted or fused, heteroaromatic ring system bound via a specific bridge, a catalyst system comprising at least one of the monocyclopentadienyl complexes, the use of the catalyst system for the polymerization or copolymerization of olefins and a process for preparing polyolefins by polymerization or copolymerization of olefins in the presence of the catalyst system and polymers obtainable in this way.

Abstract: Provided are a vinyl-biphenylpyridine monomer and a polymer thereof. More particularly, the present invention provides a vinyl-biphenylpyridine monomer having a side chain of pyridine or phenylpyridine as a functional group, a homopolymer of which molecular weight and molecular weight distribution are controlled using the monomer, and a block copolymer of which molecular structure and molecular weight are controlled to facilitate synthesis of an organic metal complex. Accordingly, the present invention provides a vinyl-biphenylpyridine monomer and a polymer thereof which are effectively used as nano and optical functional materials.

Abstract: The invention relates to compounds for selectively inhibiting human corticosteroid syntheses CYP11B1 and CYP11B2, to the production thereof and to their use for treating hypercortisolism and diabetes mellitus or insufficiency of the heart and myocardial fibrosis.

Abstract: The invention relates to the use of carboxyamine compounds and salts thereof in the treatment of HDAC dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases.

Abstract: The present invention relates to ionic liquids of low viscosity and high electrochemical stability, in particular for use in the area of electrochemistry and as solvents for carrying out chemical reactions.

Abstract: An object of the present invention is to provide an agent for use in the effective treatment and prevention of endometriosis and uterine adenomyosis. The present invention relates to an agent for use in the treatment and prevention of endometriosis or uterine adenomyosis, comprising, as an active ingredient, a compound selected from the group consisting of 3-ethylpyridine, 3-methylpyridine, 2-ethylpyridine, and 2-methylpyridine.

Abstract: A novel compound is having the structure, Formula (I): exhibits interesting odor characteristics, generally green in nature, particularly of a tomato leaf character, and so find use in perfumes and perfumed products.

Abstract: This invention provides aryl-substituted acyclic enediyne compounds of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein R1=R2=H; or R1 and R2 together form a moiety represented by the formula R3 represents a substituted or unsubstituted alkyl having 4-30 carbon atoms, or a substituted or unsubstituted aryl group having 3-30 carbon atoms; and R4 represents a substituted or unsubstituted aryl group having 3-30 carbon atoms; with the proviso that R3 is not butyl, pentyl, tetrahydropyranyloxymethyl, tetrahydropyranyloxypropyl or phenyl when R1=R2=H and R4 is o-cyanophenyl,; and with the proviso that R3 is not butyl when R1=R2=H and R4 is phenyl. The compounds of formula (I) are found to have inhibitory activities against topoisomerase I or act as a S phase or G2/M phase blocker.

Abstract: Corticotropin-releasing factor (CRF) antagonists having the formulae wherein the dashed lines, A, B, Y, Z, G, R3, R4, R5, R6, R16 and R17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.

Abstract: Photoacid generators (PAGs) comprising photoactive moieties and perfluorinated, multifunctional anionic moieties (or incipient anionic moieties) are disclosed which provide photoacids with high acid strength, low volatility and low diffusivity. The present invention further relates to photoacid generators as they are used in photoinitiated or acid-catalyzed processes for uses such as photoresists for microlithography and photopolymerization.

Abstract: Disclosed herein are compounds of formula II: wherein Alk, Z, X1, X2, R1, —R10 and R11 are defined herein, and their salts and pharmaceutically acceptable derivatives thereof, as well as other compounds of the general formula Het-A-Alk-W-Ar-C(X2)?NO-X2 where Het, A, W and Ar are also defined herein. These compounds are useful in treating picornavirus infections in mammals. Novel intermediates of these compounds, as well as pharmaceutical compositions and methods of use, are also disclosed herein.

Abstract: Compounds of the formula (I), in which M is a central building block selected from the group below in which A1, A2, K1 and K2 are as defined in the description, are novel effective tryptase inhibitors.

Abstract: There are disclosed a process for producing a coupling compound of formula (1): (Y—)(n?1)R1—R2—(R1)(n??1),??(1) wherein R1 and R2 independently represent a substituted or unsubstituted aryl group, which process is characterized by reacting an unsaturated organic compound of formula (2): n?(R1X1n)??(2) wherein n, n?, and R1 are the same as defined above, and X1 is the same or different and independently represents a leaving group and bonded with a sp2 carbon atom of R1 group, with a boron compound of formula (3): m{R2(BX22)n?}??(3) wherein R2 and n? are the same as defined above, X2 represents a hydroxy group, an alkoxy group, in the presence of a catalyst containing (A) a nickel compound, and (B) a nitrogen-containing cyclic compound, and the catalyst.

Abstract: A process for preparing compounds of the formula (II), where the substituents R1 to R5 are each independently H, CH3, straight-chain or branched C1–C8-alkyl, CH(OC1–C5-alkyl)2, CH(C1–C5-alkyl)(OC1–C5-alkyl), CH2(OC1–C5-alkyl), CH(CH3)(OC1–C5-alkyl), C1–C8-alkoxy, N(C1–C5-alkyl)2, phenyl, substituted phenyl, aryl, heteroaryl, S(C1–C5-alkyl) or a radical Caryl, alkyl, and the symbols X1 to 5 are each carbon or a maximum of two neighboring X1-5 are nitrogen or X1R1 and X2R2 together are O, NH, N(C1–C5-alkyl), N(C?O—C1–C5-alkyl), N(SiR3)2 or S, or where neighboring radicals R1 to R5 form the following structural unit, where X6 to X9 and R6 to R9 have the same meaning as X1 to X5 and R1 to R5 which comprises reacting chloro- or fluoroaromatics of the formula (I) with carbon electrophiles and lithium metal.

Abstract: The present invention relates to novel water-soluble, stable derivatives of combretastatin A-4, and novel synthesis methods therefore. The combretastatin A-4 prodrugs described herein appear to be useful in the treatment of neoplastic disease.

Abstract: The invention relates to the preparation of aryl-aryl coupled compounds and materials. These materials play an important role in industry, for example as liquid crystals, pharmaceuticals and agrochemicals, to mention just a few application areas. These compounds, in particular, are also of major importance especially in the high-growth area of organic semi-conductors (for example, applications in organic or polymeric light-emitting diodes, organic solar cells, organic ICs).

Abstract: A process for preparing an ionic liquid or salt, formed by reaction between an organic base and an alkylating agent, wherein the alkylating agent is a fluorinated ester or an alkyl sulfonate, is described. Suitable organic bases include imidazoles, substituted imidazoles, pyridines and substituted pyridines. The so-formed products can be subsequently transformed into different ionic liquids or salts by metathesis.

Abstract: A fluorescent dye, a structure of a fluorescent storage media and method using thereof, are disclosed. The fluorescent dye of the present invention comprises an organic violet fluorescent compound having a chemical structure (I) is suitable for using a short wavelength laser having a wavelength less than 500 nm as an excitation source. When a short wavelength laser is used for exciting the organic violet fluorescent compound (I), a fluorescence having an emission wavelength larger than 500 nm is induced, and a reading signal can be provided by detecting the intensity of the fluorescence radiation.

Abstract: Based on the discovery that the melting point and solubility of onium salts are affected by the asymmetry of the substitution on cation, and that the branched substituents effectively shield onium cations from electrochemical reduction, new onium salts are synthesized and high performance electrolytes based on these salts for electrochemical capacitor are provided. The composition of the new electrolyte comprises an onium salt or mixture of such onium salts dissolved in aprotic, non-aqueous solvents or mixture of such solvents. The electrolyte is able to perform at high rate of charge/discharge, at low ambient temperatures, and within wide operating voltage, due to the high solubility, low melting temperature, and the improved reduction stability of the new onium cations, respectively.

Abstract: The invention relates to a process for carrying out a homogeneously catalyzed C—C coupling reaction between an optionally substituted (hetero)aromatic bromide compound and a second reactant, which is chosen from the group of olefins in which at least one of the substituents on the olefinic sp2 carbon atoms is a hydrogen atom, and the group of organoboron compounds with the formula Ar—B(OR1)—OR2, where Ar stands for an optionally substituted (hetero)aryl group and R1 and R2 each independently represent H or an alkyl group or, together with the O-atoms to which they are bound and the B-atom, form a ring with 2-5 C-atoms, in the presence of an aprotic dipolar solvent and a base, a palladium salt without a ligand being used as palladium catalyst and the reaction being carried out at a ratio between the quantity of palladium present in the palladium salt and the optionally substituted (hetero)aromatic bromine compound of between 0.00001 and 0.1 mol %, preferably between 0.01 and 0.1 mol %.

Abstract: A process for preparing compounds of the formula (II), where the substituents R1 to R5 are each independently H, CH3, straight-chain or branched C1-C8-alkyl, CH(OC1-C5-alkyl)2, CH(C1-C5-alkyl)(OC1-C5-alkyl), CH2(OC1-C5-alkyl), CH(CH3)(OC1-C5-alkyl), C1-C8-alkoxy, N(C1-C5-alkyl)2, phenyl, substituted phenyl, aryl, heteroaryl, S(C1-C5-alkyl) or a radical Caryl, alkyl, and the symbols X1 to 5 are each carbon.

Abstract: A process for the production of compounds Ar—R1 by means of a cross-coupling reaction of an organometallic reagent R1—M with an aromatic or heteroaromatic substrate Ar—X catalyzed by one or several iron salts or iron complexes as catalysts or pre-catalysts, present homogeneously or heterogeneously in the reaction mixture. This new invention exhibits substantial advantages over established cross coupling methodology using palladium- or nickel complexes as the catalysts. Most notable aspects are the fact that (i) expensive and/or toxic nobel metal catalysts are replaced by cheap, stable, commercially available and toxicologically benign iron salts or iron complexes as the catalysts or pre-catalysts, (ii) commercially attractive aryl chlorides as well as various aryl sulfonates can be used as starting materials, (iii) the reaction can be performed under “ligand-free” conditons, and (iv) the reaction times are usually very short.

Abstract: An unsaturated derivative at the 4-position of 6-tert-butyl-1,1-dimethylindane corresponding to the following formula: in which: X represents: a divalent radical of formula: and Y represents a divalent radical of following formula: R1 represents —CH3, —(CH2)p—OR4, —(CH2)p—COR5 or —S(O)t—R6, p being 0, 1, 2 or 3, t being 0, 1 or 2, R4 represents H, lower alkyl, —COR7, aryl, aralkyl, mono- or polyhydroxyalkyl, or a polyether radical, R5 represents H, lower alkyl, —OR8 or R6 represents H or lower alkyl, R7 represents lower alkyl, R8 represents H, alkyl, alkenyl, alkynyl, aryl, aralkyl, mono- or polyhydroxyalkyl, a sugar residue selected from the group consisting of residues deriving from glucose, galactose, mannose and glucuronic acid or an amino acid residue deriving from lysine, glycine and aspartic acid, r′ and r″, which are identical or different, represent H, low

Abstract: A compound is provided having the formula: 1

Abstract: The present invention relates to vinyl-phenyl monomers and polymers prepared therefrom. More particularly, the present invention is to provide the vinyl-phenyl monomers expressed by formula (1) which are capable of various polymerization such as radical polymerization, cation polymerization, anion polymerization and metallocene catalyzed polymerization due to resonance effect of phenyl group and changing characteristics variously and thus, suitable in the synthesis of general-purpose polymers which can be used in photo-functional materials by forming a complex with a metal component having an optical characteristic.

Abstract: The present invention concerns a process for arylating or vinylating or alkynating a nucleophilic compound. More particularly, the invention concerns arylating nitrogent-containing organic derivatives. The arylating or vinylating or alkynating process of the invention consists of reacting a nucleophilic compound with a compound carrying a leaving group and is characterized in that the reaction is carried out in the presence of an effective quantity of a catalyst based on a metallic element M selected from groups (VIII), (Ib) and (IIb) of the periodic table and at least one at least bidentate ligand comprising at least two chelating atoms, namely at least one oxygen atom and at least one nitrogen atom.

Abstract: There is disclosed a method for producing a biaryl compound of formula (I): 1

Abstract: Methods are provided for the construction of unsymmetrical biaryl compounds and alkylated aromatic compounds from arylnitriles using a nickel or palladium catalyzed coupling in which the catalyst has at least one phosphine or phosphite ligand.

Abstract: The present invention relates to substituted indane or dihydroindole compounds of Formula (I) wherein A is an indole. These compounds have high affinity for D4 receptors.

Abstract: The present invention relates to vinyl-phenyl monomers and polymers prepared therefrom.

Abstract: The present invention is a novel intermediate, compound of the formula (VI) 1

Abstract: A process for preparing compounds of the formula (II), 1

Abstract: The present invention relates to vinyl-phenyl monomers and polymers prepared therefrom. More particularly, the present invention is to provide the vinyl-phenyl monomers expressed by formula (1) which are capable of various polymerization such as radical polymerization, cation polymerization, anion polymerization and metallocene catalyzed polymerization due to resonance effect of phenyl group and changing characteristics variously and thus, suitable in the synthesis of general-purpose polymers which can be used in photo-functional materials by forming a complex with a metal component having an optical characteristic.

Abstract: The present invention provides a process for synthesis of tri- and tetra-alkylated pyridines (i.e. collidines) in high yields by reacting methyl ethyl ketone with formaldehyde in presence of ammonia in gas phase in the presence of a zeolite catalyst which comprises of silica-alumina with at least one metal ion and/or metal selected from the group consisting of lanthanum, lead, manganese, iron, copper and cobalt. This process provides eco-friendly, more economical and shape-selective heterogeneous method.

Abstract: The present invention provides an improved process for the synthesis of aryl pyridine bases by reacting an aromatic aldehyde or ketone and allylic alcohol or aldehyde in presence of ammonia in gas phase, in high yield and selectivity with catalyst obtained by optionally modifying a zeolite having an atomic ratio of Si to Al, 2.5 to 12.5 and /or with at least one metal ion and/or metal compound selected from the group consisting of lead and lanthanum. This process provides an eco-friendly, more economical and highly selective heterogeneous method.

Abstract: Compounds of the Formula 1, Formula 2, Formula 3 and Formula 4 wherein the symbols have the meaning assigned to them in the disclosure have retinoid-like biological activity.

Abstract: Compounds of Formula 1 and of Formula 2 where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist or retinoid negative hormone like biological activity.

Abstract: Aromatic methylidene compounds of the following general formula 1

Abstract: The invention relates to a process for the preparation of 1,2,3,6-tetrahydro 2,2,6,6-tetramethylpyridine N-oxide by the catalytic oxidation of 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridine, wherein 1,2,3,6-tetrahydro-2,2,6,6-tetramethylpyridine is oxidized with hydrogen peroxide in an aqueous medium in the presence of an alkaline earth metal salt or hydroxide as catalyst. The product is a polymerization inhibitor for monomers.

Abstract: Described is a process for preparing 1-(2-sulfoethyl)pyridinium betaine wherein pyridine is reacted with a sulfoethylating agent from the group consisting of carbyl sulfate, ethionic acid and its salt and vinylsulfonic acid and vinylsulfonate, the reaction taking place in aqueous solution or in pyridine.